High Out-of-Pocket Costs Reduce Adherence to GLP-1 Weight Loss Medications
A recent study published in JAMA Health Forum highlights a concerning trend regarding the adherence rates of patients prescribed GLP-1 medications for weight loss. The research, which analyzed data from 8,914 patients over a period of 1.5 years, found that many patients struggle to maintain their prescriptions primarily due to high out-of-pocket costs. The study categorized the costs of GLP-1s into five tiers: $0-$21, $22-$43, $44-$75, $75-$168, and over $168. Alarmingly, even at the lowest cost tier, a significant number of patients—approximately three out of four—discontinued their medication within a year of starting. However, the study revealed a critical tipping point at $75; once monthly out-of-pocket costs exceeded this amount, nonadherence surged to over 80%. Lead author Eunhae Shin, an assistant professor of health policy and management at the University of Georgia, expressed surprise at the findings, noting that she initially expected a straightforward linear relationship between higher costs and lower adherence. Instead, adherence remained relatively consistent until reaching the $75 threshold. The study also points out that various factors contribute to low adherence rates for GLP-1s, including potential side effects and insurance policies that may complicate access to these medications. Although not directly measured, factors such as mid-year insurance policy changes, prior authorization requirements, and step therapy protocols can disrupt patients' ability to continue their prescriptions. Shin emphasized the importance of understanding the financial implications of medication adherence, stating, "The key takeaway from our study is that out-of-pocket costs matter." This issue is particularly timely given ongoing discussions in the policy arena regarding medication affordability. While federal programs have set limits on out-of-pocket spending for eligible Medicare patients at $50, commercial insurers have yet to adopt similar caps, leaving many individuals with employer-sponsored insurance facing significant financial barriers. The study found that the lowest adherence rates—around 17%—were observed among patients incurring costs of $168 or more monthly. This group was more likely to reside in Southern states and have high-deductible insurance plans. While socioeconomic factors were not directly analyzed in this study, previous research indicates that low-income populations often enroll in plans with high cost-sharing and low premiums, which can exacerbate the financial burden of GLP-1 medications. Shin noted that vulnerable populations are disproportionately affected by these high costs, leading to lower rates of medication adherence. The implications of obesity are profound, increasing the risk of chronic health conditions such as heart disease and type 2 diabetes. Despite the immediate financial challenges associated with weight loss medications, Shin remains hopeful that future research will demonstrate long-term economic benefits. She stated, "Although the out-of-pocket cost can be sizeable in the short run, potentially in the long run we are able to better manage chronic conditions with these medications. If you can reduce emergency department visits and hospitalizations, that could lead to long-term cost savings."




